Biocon Biologics, a subsidiary of Biocon, has agreed to acquire Viatris’ biosimilar business in a cash-and-stock deal worth up to US$3.335 B. The companies have a long-standing biosimilar partnership and now Viatris is handing over the business to its partner,creating one of the broadest commercialised portfolios in the industry. The acquisition provides Biocon access to Viatris’ global commercial infrastructure and strong biosimilar portfolio in diabetes, oncology, immunology and other non-communicable diseases.